ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
7,921.30
0.76%
S&P ASX All Technology
3,078.20
0.32%
Brent Oil
79.745
-2.20%
US Dollar vs AUD
1.52742
-0.09%
Bitcoin
67,888.58
3.19%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. OSE Immunotherapeutics (OSE)

  7. OSE Immunotherapeutics (OSE) News

OSE

OSE Immunotherapeutics (OSE)

OSE Immunotherapeutics
Date:
Sort by:
 Showing the most relevant articles for your search:EU:OSE
DateTimeSourceHeadlineSymbolCompany
24/07/202416:55GlobeNewswire Inc.OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative ColitisEU:OSEOSE Immunotherapeutics
04/07/202402:00GlobeNewswire Inc.Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371EU:OSEOSE Immunotherapeutics
04/07/202402:00GlobeNewswire Inc.Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371EU:OSEOSE Immunotherapeutics
04/07/202402:00GlobeNewswire Inc.OSE Immunotherapeutics et Boehringer Ingelheim poursuivent l’avancée du développement clinique du traitement first-in-class SIRPα BI 770371 en immunologie du cancerEU:OSEOSE Immunotherapeutics
03/07/202402:00GlobeNewswire Inc.Informations relatives au nombre total de droits de vote et d’actions composant le capitalEU:OSEOSE Immunotherapeutics
01/07/202415:30GlobeNewswire Inc.OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’EU:OSEOSE Immunotherapeutics
01/07/202415:30GlobeNewswire Inc.OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’ EU:OSEOSE Immunotherapeutics
01/07/202415:30GlobeNewswire Inc.OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’EU:OSEOSE Immunotherapeutics
24/06/202415:30GlobeNewswire Inc.OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell TherapiesEU:OSEOSE Immunotherapeutics
24/06/202415:30GlobeNewswire Inc.OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell TherapiesEU:OSEOSE Immunotherapeutics
24/06/202415:30GlobeNewswire Inc.OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-TEU:OSEOSE Immunotherapeutics
20/06/202415:30GlobeNewswire Inc.OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)EU:OSEOSE Immunotherapeutics
20/06/202415:30GlobeNewswire Inc.OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)EU:OSEOSE Immunotherapeutics
20/06/202415:30GlobeNewswire Inc.OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San Francisco (18 – 21 juin)EU:OSEOSE Immunotherapeutics
20/06/202402:15GlobeNewswire Inc.OSE Immunotherapeutics présente les résultats de l’Assemblée générale 2024 et l’évolution du Conseil d’administration prêt à conduire la stratégie de croissance de la SociétéEU:OSEOSE Immunotherapeutics
20/06/202402:15GlobeNewswire Inc.OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s GrowthEU:OSEOSE Immunotherapeutics
20/06/202402:15GlobeNewswire Inc.OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s GrowthEU:OSEOSE Immunotherapeutics
13/06/202402:00GlobeNewswire Inc.OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin BesseEU:OSEOSE Immunotherapeutics
13/06/202402:00GlobeNewswire Inc.OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin BesseEU:OSEOSE Immunotherapeutics
13/06/202402:00GlobeNewswire Inc.Webinaire KOL Investisseurs d’OSE Immunotherapeutics : le paysage thérapeutique et les besoins médicaux non satisfaits dans le cancer du poumon non à petites cellulesEU:OSEOSE Immunotherapeutics
05/06/202415:30GlobeNewswire Inc.OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénaleEU:OSEOSE Immunotherapeutics
05/06/202415:30GlobeNewswire Inc.OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal TransplantEU:OSEOSE Immunotherapeutics
05/06/202415:30GlobeNewswire Inc.OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal TransplantEU:OSEOSE Immunotherapeutics
05/06/202402:00GlobeNewswire Inc.Informations relatives au nombre total de droits de vote et d’actions composant le capitalEU:OSEOSE Immunotherapeutics
31/05/202402:15GlobeNewswire Inc.OSE Immunotherapeutics Provides Business and Corporate UpdateEU:OSEOSE Immunotherapeutics
31/05/202402:15GlobeNewswire Inc.OSE Immunotherapeutics Provides Business and Corporate UpdateEU:OSEOSE Immunotherapeutics
31/05/202402:15GlobeNewswire Inc.OSE Immunotherapeutics fait le point sur ses avancées et sur la stratégie de croissance de la SociétéEU:OSEOSE Immunotherapeutics
30/05/202402:00GlobeNewswire Inc.Mise à disposition des documents préparatoires à l’Assemblée générale mixte du 19 juin 2024EU:OSEOSE Immunotherapeutics
22/05/202415:30GlobeNewswire Inc.OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseasesEU:OSEOSE Immunotherapeutics
22/05/202415:30GlobeNewswire Inc.OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseasesEU:OSEOSE Immunotherapeutics
 Showing the most relevant articles for your search:EU:OSE

Your Recent History

ASX
QBE
QBE Insurance
ASX
TLS
Telstra
ASX
ANZ
Australia And New Zealan...
ASX
CBA
Commonwealth Bank Of Aus...
ASX
AMP
AMP
ASX
NAB
National Australia Bank
SPI
SP500
S&P 500
ASX
FMG
Fortescue
ASX
NCM
Newcrest Mining
ASX
SUN
Suncorp
FX
AUDJPY
AUD vs Yen
PM
XAUUSD
Gold vs US Dollar
ASX
RIO
Rio Tinto
ASX
XFL
S&P ASX 50
NYSE
VZ
Verizon Communications
NYSE
XOM
Exxon Mobil
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved